Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study

[1]  Y. Nabeya,et al.  Surgical treatment strategy for esophagogastric junction cancers based on the tumor diameter , 2019, BMC Surgery.

[2]  Florence E. Turrentine,et al.  The negative effect of perioperative red blood cell transfusion on morbidity and mortality after major abdominal operations. , 2018, American journal of surgery.

[3]  Yu-Shang Yang,et al.  Strategies of nodal staging of the TNM system for esophageal cancer. , 2018, Annals of translational medicine.

[4]  Zongguang Zhou,et al.  Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988–2012 , 2015, Annals of surgery.

[5]  Wanqing Chen,et al.  Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries , 2015, Thoracic cancer.

[6]  T. Yoshikawa,et al.  Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  Zongguang Zhou,et al.  Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China , 2015, Medicine.

[8]  James Y. Dai,et al.  Esophageal Adenocarcinoma and Its Rare Association with Barrett’s Esophagus in Henan, China , 2014, PloS one.

[9]  F. Khuri,et al.  Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma , 2013, Journal of Gastrointestinal Cancer.

[10]  T. Yoshikawa,et al.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies , 2010, Gastric Cancer.

[11]  H. Welch,et al.  Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak? , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  S. Sabatino,et al.  Trends in esophageal cancer incidence by histology, United States, 1998–2003 , 2008, International journal of cancer.

[13]  J. Reitsma,et al.  Extended Transthoracic Resection Compared With Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus: Five-Year Survival of a Randomized Clinical Trial , 2007, Annals of surgery.

[14]  A. Nashimoto,et al.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. , 2006, The Lancet. Oncology.

[15]  Paul Fockens,et al.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. , 2002, The New England journal of medicine.

[16]  M. Feith,et al.  Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.

[17]  T. Wobbes,et al.  Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer , 1994, The Lancet.

[18]  J. Peters,et al.  Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?—a SEER Database Analysis , 2013, Journal of Gastrointestinal Surgery.

[19]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..